The in vitro cytotoxicities of a number of gold(I), silver(I) and copper(I) complexes containing chiral tertiary phosphine ligands have been examined against the mouse tumour cell lines P815 mastocytoma, B16 melanoma [gold(I) and silver(I) compounds] and P388 leukaemia [gold(I) complexes only] with many of the complexes having IC50 values comparable to that of the reference compounds cis-diamminedichloroplatinum(ll), cisplatin, and bis[1,2-bis(diphenylphosphino)ethane]gold(I) iodide. The chiral tertiary phosphine ligands used in this study include (R)-(2-aminophenyl)methylphenylphosphine; (R,R)-, (S,S)-and (R*,R*)-l,2-phenylenebis(methylphenylphosphine); and (R,R )-, (S,S)-and (R*, R')-bis{(2-diphenylphosphinoethyl)phenylphosphino}ethane. The in vitro cytotoxicities of gold(I) and silver(I) complexes containing the optically active forms of the tetra(tertiary phosphine) have also been examined against the human ovarian carcinoma cell lines 41M and CH1, and the cisplatin resistant 41McisR, CHlcisR and SKOV-3 tumour models. IC5o values in the range 0.01 0.04 #M were determined for the most active compounds, silver(I) complexes of the tetra(tertiary phosphine). Furthermore, the chirality of the ligand appeared to have little effect on the overall activity of the complexes: similar IC50 data were obtained for complexes of a particular metal ion with each of the stereoisomeric forms of a specific ligand.
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Introduction.
Bis(ditertiary phosphine) complexes of gold(I), silver(I) and copper(I) have attracted much interest over the past decade as certain of these complexes have been shown to display antitumour activities comparable to cis-diamminedichloroplatinum(ll), cisplatin, for example, bis[1,2-bis(diphenylphosphino)ethane]gold(I) chloride, [Au(dppe)2]CI, and its silver(I) and copper(I) derivatives. The mode of action of these complexes is not known but it is believed to be quite different to that of cisplatin. The complex [Au(dppe)2]CI has been shown to inhibit DNA, RNA and protein synthesis; to cause DNA single strand breaks; and to induce mitochondrial damage in hepatocytes. Indeed, despite the early promise of [Au(dppe)2]CI and its derivatives, the compounds have subsequently been shown to be too toxic for clinical use due to side-effects related to the disruption of mitochondrial function in hepatocytes. 2, 3 We have recently synthesised a number of related gold(I), silver(I) and copper(I) complexes containing the substituted (2-aminophenyl)phosphines AMPP [(+)-(2-aminophenyl)methylphenylphosphine] and ADPP [(2-aminophenyl) (a) Syntheses. The ligands (+)-(2-aminophenyl)methylphenylphosphine, 7 (R*,R*)-l,2-phenylenebis(methylphenylphosphine)8 and (R*, R*)-1,2-bis{(2-diphenylphosphinoethyl)phenylphosphino}-ethane 9 were synthesised and resolved following literature procedures. The complexes containing (R,R)-, (S,S)-and (R*,R*)-dias or-diph [M Ag(I) (5 mL (ii) Human ovarian carcinoma cell lines: The biological properties of the CH1,41M and SKOV-3 cell lines have been described previously. 13, 14 The celllines were grown as monolayers in Dulbecco's modified Eagle plus10% foetal calf serum, 100 lg mL -1 streptomycin, 100 #g mL 1 penicillin and 2 mM glutamine in a 5% CO2 atmosphere. The cell lines were checked regularly for mycoplasma infection. Cytotoxicity assessment was undertaken using the sulphorhodamine B assay as described previously. 14 The complexes were dissolved in dimethylsulfoxide, diluted in distilled water and added to the cultures at concentrations ranging from 0.005 to 5 l.tM in quadruplicate. The final concentration of dimethylsulfoxide in the culture medium was < 0.5%. The cells were exposed to the drug containing medium for 96 h. The IC5o values were determined as the drug concentration reducing absorption (564 nm) of sulphorhodamine B-stained wells to 50% of that of the control wells. The complexes that were used in this work are listed in Tables 1-4. We have previously described the preparation and characterisation of many of these complexes. 9,1 Complexes containing (R)-AMPP were prepared in a similar fashion to that reported for their racemic analogues. 4 
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